Market Exclusivity for Drugs with Multiple Orphan Approvals (1983–2017) and Associated Budget Impact in the US

被引：0
|
作者：
William V. Padula
Sonal Parasrampuria
Mariana P. Socal
Rena M. Conti
Gerard F. Anderson
机构：
[1] University of Southern California,Department of Pharmaceutical and Health Economics, School of Pharmacy, USC Schaeffer Center
[2] University of Southern California,Leonard D. Schaeffer Center for Health Policy and Economics
[3] Johns Hopkins Bloomberg School of Public Health,Department of Health Policy and Management
[4] Boston University Questrom School of Business,Institute for Health System Innovation and Policy
来源：
PharmacoEconomics | 2020年 / 38卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1115 / 1121
页数：6
相关论文
共 50 条
  • [21] Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period
    Sarpatwari, Ameet
    Beall, Reed F.
    Abdurrob, Abdurrahman
    He, Mengdong
    Kesselheim, Aaron S.
    HEALTH AFFAIRS, 2018, 37 (05) : 732 - 737
  • [22] Methodological Quality Assessment of Budget Impact Analyses for Orphan Drugs: A Systematic Review
    Abdallah, Khadidja
    Huys, Isabelle
    Claes, Kathleen
    Simoens, Steven
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [23] IS THE ORPHANAGE FILLING UP? PROJECTING THE GROWTH AND BUDGET IMPACT OF ORPHAN DRUGS IN EUROPE
    Flostrand, S.
    Rodriguez, I
    Maddox, B.
    Finch, L.
    Belulaj, S.
    Gould, A.
    VALUE IN HEALTH, 2016, 19 (07) : A599 - A599
  • [24] Estimating the budget impact of orphan drugs in Sweden and France 2013-2020
    Hutchings, Adam
    Schey, Carina
    Dutton, Richard
    Achana, Felix
    Antonov, Karolina
    ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [25] PRICING AND MARKET ACCESS OF ORPHAN DRUGS IN CHINA: ANALYSIS OF NATIONAL AND PROVINCIAL POLICY AND THE ASSOCIATED IMPACT ON COVERAGE
    Sherwin, G.
    Akpinar, P.
    Yap, B.
    VALUE IN HEALTH, 2016, 19 (07) : A835 - A835
  • [26] THE CURRENT AND FUTURE COSTS OF ORPHAN DRUGS IN CANADA - A PUBLIC PAYER BUDGET IMPACT ANALYSIS
    Forte, L.
    Malmberg, C.
    Mann, K.
    Jupe, K.
    Chow, G.
    Lech, R. A.
    Kulik, R.
    VALUE IN HEALTH, 2019, 22 : S855 - S855
  • [27] Trend of sales revenue by year for top selling cancer drugs in the US and the effect of loss of market exclusivity
    Kim, Myung Sun
    Haslam, Alyson
    Prasad, Vinay
    JOURNAL OF CANCER POLICY, 2025, 43
  • [28] WHAT WAS THE ACTUAL BUDGET IMPACT OF ORPHAN MEDICINAL PRODUCTS BETWEEN 2000-2017 IN EUROPE?
    Mestre-Ferrandiz, J.
    Palaska, C.
    Kelly, T.
    Hutchings, A.
    Parnaby, A.
    VALUE IN HEALTH, 2019, 22 : S854 - S854
  • [29] THE IMPACT OF OUT-OF-POCKET SPENDING ON THE PENETRATION OF GENERIC DRUGS AFTER THE EXPIRY OF THE MARKET EXCLUSIVITY
    Cioni, L.
    Tettamanti, A.
    Urbinati, D.
    VALUE IN HEALTH, 2019, 22 : S607 - S607
  • [30] TRENDS IN APPROVALS AND PRICE AT MARKET ENTRY OF NEW DRUGS FOR BREAST CANCER IN THE US (1980-2022)
    Althomali, A.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2023, 26 (06) : S110 - S110
12345